LeMaitre Vascular Inc (LMAT)
74.22
+7.45
(+11.16%)
USD |
NASDAQ |
May 03, 16:00
74.28
+0.06
(+0.08%)
After-Hours: 20:00
LeMaitre Vascular Research and Development Expense (Quarterly): 4.351M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 4.351M |
| September 30, 2023 | 4.224M |
| June 30, 2023 | 4.516M |
| March 31, 2023 | 3.875M |
| December 31, 2022 | 3.554M |
| September 30, 2022 | 3.462M |
| June 30, 2022 | 3.346M |
| March 31, 2022 | 2.932M |
| December 31, 2021 | 3.457M |
| September 30, 2021 | 2.848M |
| June 30, 2021 | 2.652M |
| March 31, 2021 | 2.844M |
| December 31, 2020 | 2.869M |
| September 30, 2020 | 2.098M |
| June 30, 2020 | 2.139M |
| March 31, 2020 | 2.994M |
| December 31, 2019 | 2.499M |
| September 30, 2019 | 2.281M |
| June 30, 2019 | 2.256M |
| March 31, 2019 | 2.24M |
| December 31, 2018 | 2.347M |
| September 30, 2018 | 2.037M |
| June 30, 2018 | 1.988M |
| March 31, 2018 | 1.825M |
| December 31, 2017 | 1.583M |
| Date | Value |
|---|---|
| September 30, 2017 | 1.761M |
| June 30, 2017 | 1.634M |
| March 31, 2017 | 1.658M |
| December 31, 2016 | 1.522M |
| September 30, 2016 | 1.539M |
| June 30, 2016 | 1.634M |
| March 31, 2016 | 1.446M |
| December 31, 2015 | 1.575M |
| September 30, 2015 | 1.421M |
| June 30, 2015 | 1.331M |
| March 31, 2015 | 1.152M |
| December 31, 2014 | 1.081M |
| September 30, 2014 | 1.109M |
| June 30, 2014 | 1.137M |
| March 31, 2014 | 1.344M |
| December 31, 2013 | 1.402M |
| September 30, 2013 | 1.30M |
| June 30, 2013 | 1.268M |
| March 31, 2013 | 1.273M |
| December 31, 2012 | 1.561M |
| September 30, 2012 | 1.261M |
| June 30, 2012 | 1.135M |
| March 31, 2012 | 1.135M |
| December 31, 2011 | 1.139M |
| September 30, 2011 | 0.974M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.098M
Minimum
Sep 2020
4.516M
Maximum
Jun 2023
3.116M
Average
2.932M
Median
Mar 2022
Research and Development Expense (Quarterly) Benchmarks
| Baxter International Inc | 176.00M |
| AtriCure Inc | 19.84M |
| Integer Holdings Corp | 15.75M |
| ICU Medical Inc | 22.41M |
| UFP Technologies Inc | -- |